Back to top

Regeneron (REGN) Q2 Earnings Beat Estimates
August 03, 2017

Read MoreHide Full Article

Tarrytown, NY-based Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of serious medical conditions including eye diseases, high LDL cholesterol. Currently, the company has three marketed products in its portfolio – Eylea, Arcalyst and Praluent.

Eye drug, Eylea, should continue to remain the key growth driver contributing significantly to the top line. The FDA recently approved its Dupixent (dupilumab) Injection for the treatment of adults with moderate-to-severe atopic dermatitis (AD). In Jan 2017, Kevzara (sarilumab), an anti interleukin (IL)-6 receptor monoclonal antibody was approved in Canada for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response to or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs. In May 2017, the FDA also approved Kevzara for the same indication.  In Jun 2017, the European Medicine Agency`s (EMA) also approved the drug for the same indication.

In this scenario, investor focus should remain on the performance of Eylea apart from the usual top-and bottom-line numbers.

Regeneron’s performance has been mixed so far. In the last four reported quarters, it surpassed earnings estimates on two occasions and missed in two. Overall, the company has recorded an average positive earnings surprise of 0.45%.

Currently, Regeneron has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Regeneron’s second-quarter 2017 earnings beat expectations. Our consensus called for EPS of $2.67 and the company reported EPS of $3.88 (including the impact of share-based compensation expenses and tax adjustments).

Revenues: Revenues in the reported also surpassed expectations. Regeneron posted revenues of $1.47 billion, compared to our consensus estimate of $1.36 billion.

Key Stats: Eylea net sales increased 11% year over year to $919 million in the U.S. Regeneron expects U.S. Eylea net sales to grow approximately in 2017.

Check back later for our full write up on this REGN earnings report later!

More Stock News: Tech Opportunity Worth $386 Billion in 2017

From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future. Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Regeneron Pharmaceuticals, Inc. (REGN) - free report >>


More from Zacks Tale of the Tape

You May Like